Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis.
暂无分享，去创建一个
M. Blinkenberg | J. Frederiksen | I. Galea | F. Sellebjerg | S. Cramer | H. Simonsen | U. Lindberg | M. Vestergaard | A. Varatharaj | M. H. Knudsen | H. Larsson